Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma
TNB383B.0001/M22-466
Phase 1 other active
Quick answer
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma for Relapsed or refractory multiple myeloma is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Relapsed or refractory multiple myeloma
- Phase
- Phase 1
- Modality
- other
- Status
- active